We have performed immunohistochemical studies on muscle tissue of three 12 week old fetuses at risk for DMD, using antisera directed against regions located NH2-proximally and centrally in the rod shaped spectrin-like domain and against the COOH-terminus of dystrophin. All three fetuses had a family history ofDMD. Truncateddystrophins were identified in all three cases by a positive reaction with the NH2-proximal antibody, different reactions with the central antibody, and a negative reaction with the COOH-terminal antibody. These data indicate that a panel of antibodies would, in principle, permit 'immunological' mapping of dystrophin mutations. This is diagnostically important in the 35% of families where no mutation is detectable at the DNA level. Secondly, by using this mapping technique it may also become possible to identify the at risk haplotype when DNA analysis is not informative. This may be of great value in DMD carrier detection.
(1 in 3500 live male births) progressing to death in early adulthood. The milder Becker muscular dystrophy (BMD) has a later age of onset, but is caused by mutations in the same gene. DNA technology has allowed reliable diagnosis with more than 990/o certainty in most familial DMD cases. 1-5 Dystrophin, 6 the DMD gene product, has been localised in the sarcolemma of the muscle cell.7'10 In muscle biopsies of Duchenne patients no dystrophin can be detected, whereas in BMD patients dystrophin of abnormal size or quantity is observed.7 The combined results of protein and DNA studies4 [12] [13] [14] [15] have confirmed the hypothesis'6 that the Duchenne phenotype might be caused by an 'out of frame' mutation of the gene, although some exceptions have been found. The mutations produce a prematurely terminated protein, which is apparently unstable and thus degraded. Similarly, BMD is caused by 'in frame' mutations, resulting in a partly functional protein of altered molecular weight. In a preliminary study of muscle tissue ofa fetus at risk for DMD, truncated dystrophin was detected immunohistochemically. 17 The presence of abnormal dystrophin early in development indicates that its degradation takes place at a later stage. We describe here the presence of truncated dystrophins in two more fetuses at risk for DMD using antisera raised against three different regions of dystrophin and discuss the implications for fetal dystrophin analysis and the pinpointing of undetectable DMD mutations.
Materials and methods

PRENATAL DIAGNOSIS
Case I ( fig IA) The proband (5) is a carrier and two of her brothers died of DMD at the ages of 14 and 19 years. A brother of the grandmother (carrier) also died very young. within the sarcoplasma between the distal nuclei and the myotendinous junction.28 This distribution was found in the present study for all three antibodies (fig  4 A, B, C, arrows) . The proximal 30 kd antibody (AB) clearly stains the same region of the myotubes in all three Duchenne fetuses (fig 4 D, G, J) . In contrast, with the P20 antibody, the dystrophin signal was absent from the myotubes of fetus 1 (fig 4 E) , while it was present in fetuses 2 and 3 (fig 4 H, K) . Finally, none of the three Duchenne fetuses showed any signal with the COOH-terminal antibody 1460 (fig 4  F, I, L) . We noted that the muscle tissue of fetus 1 consistently and reproducibly stained very slightly above background with the P20 antibody, although this is difficult to visualise photographically (in fig 4  E ). As the P20 antibody spans the region of the gene duplication of this fetus, a small portion of the epitopes should still be detectable. More precise mapping of this duplication mutation has not yet been possible. (fig 3) and 1460 (fig 4 F, I, L) 
Discussion
